Whole Genome Sequencing Diagnoses 47% of Pediatric Neurological Cases, Reshaping the Rare Disease Workup

Whole genome sequencing is cementing its role as a first-line diagnostic tool for children with unexplained neurological conditions, according to findings published this week. A diagnostic yield of 47% in pediatric neurological cases represents a landmark data point for the clinical genomics community, one that is likely to accelerate the ongoing debate about where WGS sits in the standard of care for rare and undiagnosed disease.

The Clinical Case for Whole Genome Sequencing

For decades, the diagnostic odyssey for children with neurological disorders has been defined by frustration — years of inconclusive tests, specialist referrals, and families left without actionable answers. Traditional approaches, including targeted gene panels and chromosomal microarrays, have provided meaningful but incomplete coverage of the mutational landscape underlying conditions such as epilepsy, neurodevelopmental delay, and movement disorders. Whole genome sequencing changes the calculus fundamentally by interrogating all approximately three billion base pairs of a patient's DNA in a single assay, capturing single nucleotide variants, structural variants, and copy number alterations that panel-based approaches would routinely miss. A nearly 50% diagnostic rate in a notoriously heterogeneous patient population is a result that commands serious attention from both clinicians and laboratory directors.

What a 47% Yield Means for Lab Strategy

For genomics professionals evaluating their test menus, a diagnostic yield at this level reframes the cost-benefit conversation around WGS. Historically, laboratories have positioned whole genome sequencing as a last resort after panel testing and whole exome sequencing have failed, largely on the basis of turnaround time, cost, and the interpretive burden of variants of uncertain significance. The pediatric neurology data challenges that sequencing hierarchy directly. When nearly half of patients receive a molecular diagnosis that would otherwise have remained elusive, the argument for deploying WGS earlier in the clinical pathway becomes difficult to dismiss on economic grounds alone, particularly given the downstream savings associated with ending prolonged diagnostic workups. Laboratories that have already invested in high-throughput short-read sequencing infrastructure are well positioned to capture this clinical volume as ordering patterns evolve.

What's Next for Pediatric Genomics

The broader implications extend beyond the neurology clinic. If WGS can achieve comparable yields in other pediatric subspecialties — cardiology, metabolic medicine, immunology — the pressure on payers to expand reimbursement coverage will intensify considerably. Health systems and integrated delivery networks are watching yield data of this kind closely, as it provides the evidence base needed to justify protocol changes and coverage submissions. Regulatory bodies are similarly attentive, given that clinical utility data directly informs the framework for laboratory-developed test oversight.

A diagnostic yield of 47% in one of medicine's most diagnostically challenging populations signals that whole genome sequencing is no longer a specialized last resort but an essential component of the modern genetic testing laboratory's core offering.